EVMN

Evommune Inc

5.21

Oct 22 • 3:59 PM ET +0.04 (0.77%)

5.12

Aftermarket • 5:00 PM ET -0.09 (-1.73%)

Healthcare Biotechnology USA Micro NYSE

Peers: ACRS ATTO JSPR UPB ZURA ALMS AVTX ORKA CNTB JBIO

| Held by: VTI VXF IWM FESM IWO VTWO SCHA VHT IWC SBIO

Scroll to Statements

Index	RUT
Market Cap	189.08M
Enterprise Value	-3.08M
Income	-94.67M
Sales	10.00M
Book/sh	7.65
Cash/sh	5.53
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	48
IPO	Nov 06, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	18.91
P/B	0.68
P/C	0.94
P/FCF	-
EV/EBITDA	-
EV/Sales	-0.31
Quick Ratio	11.68
Current Ratio	11.68
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-2.83
EPS next Y	-3.56
EPS next Q	-0.83
EPS this Y	69.25%
EPS next Y	-3.32%
EPS next 5Y	32.93%
EPS past 3/5Y	-38.91% -
Sales past 3/5Y	61.25% -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-97.87%
Sales Q/Q	-
Earnings	Aug 06 AMC
EPS/Sales Surpr.	-33.94% -100.00%

Insider Own	38.83%
Insider Trans	-0.63%
Inst Own	68.49%
Inst Trans	-1.18%
ROA	-47.55%
ROE	-178.03%
ROIC	-33.28%
Gross Margin	84.62%
Oper. Margin	-1018.93%
Profit Margin	-946.68%
SMA20	-19.59%
SMA50	-46.84%
SMA200	-71.33%
Trades

Shs Outstand	36.28M
Shs Float	22.20M
Short Float	13.03%
Short Ratio	4.28
Short Interest	2.89M
52W High	33.20 -84.31%
52W Low	5.09 2.36%
Volatility	8.35% 7.48%
ATR (14)	0.50
RSI (14)	20.84
Beta	-
Rel Volume	0.38
Avg Volume	675.81K
Volume	255,646

Perf Week	-12.14%
Perf Month	-40.59%
Perf Quarter	-54.14%
Perf Half Y	-79.84%
Perf YTD	-69.57%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.54
Target Price	22.40
Prev Close	5.17
Price	5.21
Change %	0.77%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-26	Resumed	Morgan Stanley	Overweight	$26
Oct-12-26	Initiated	UBS	Neutral	$8
Aug-26-26	Initiated	Needham	Buy	$28
Jun-30-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-29-26	Downgrade	William Blair	Outperform → Mkt Perform
May-01-26	Initiated	Stifel	Buy	$54
Apr-07-26	Resumed	Oppenheimer	Outperform	$50
Jan-22-26	Initiated	Oppenheimer	Outperform	$42
Jan-08-26	Initiated	Raymond James	Strong Buy	$40
Jan-06-26	Initiated	H.C. Wainwright	Buy	$35
Dec-01-25	Initiated	William Blair	Outperform
Dec-01-25	Initiated	Morgan Stanley	Overweight	$36
Dec-01-25	Initiated	Leerink Partners	Outperform	$42
Dec-01-25	Initiated	Evercore ISI	Outperform	$40
Dec-01-25	Initiated	Cantor Fitzgerald	Overweight

Show Previous Ratings

Oct-05-26 07:57AM	EADV26: Key late-stage readouts from the conference (Clinical Trials Arena)
Oct-01-26 08:00AM	Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress (Business Wire) -12.71%
Sep-23-26 04:05PM	Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress (Business Wire) -8.65%
Sep-11-26 05:37AM	Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use (BioPharma Dive)
Sep-09-26 10:03AM	This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On (Investor's Business Daily) -17.13%
07:51PM	Loading…
Sep-08-26 07:51PM	Why Is EVMN Stock Down 13% After-Hours? (Stocktwits) +6.60%
05:43PM	Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis (Business Wire)
Jul-30-26 08:00AM	Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis (Business Wire)
Jun-29-26 11:28AM	Evommune terminates oral drugs development in CSU (Clinical Trials Arena) -40.23%
10:16AM	Evommune Shares Slide After Phase 2b CSU Trial Misses Main Goal (EVMN) (InvestorsHub)
08:30AM	Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria (Business Wire)
May-07-26 04:05PM	Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights (Business Wire) -5.58%
Apr-10-26 04:00AM	Biotechs IPO comeback; Trumps tariff loophole for pharma (Pharma Voice) -10.96%
Apr-07-26 04:00AM	Evommune bucked biotech IPO drought and is focused on the long game (Pharma Voice)
Apr-06-26 09:00AM	Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine (Business Wire)
08:15AM	Loading…
Mar-23-26 08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
Mar-18-26 01:16PM	Evommune Stock Sees RS Rating Rise To 91 (Investor's Business Daily)
09:34AM	Block upgraded, Starbucks downgraded: Wall Street's top analyst calls (The Fly)
Mar-05-26 04:01PM	Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights (Business Wire) +6.36% +5.62%
Feb-25-26 10:27AM	Evommune CEO Luis Pena Reveals Whats Behind Companys Post-IPO Success (NYSE) +7.10%
Feb-15-26 09:59AM	Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Benzinga)
Feb-12-26 08:30PM	Evommune Announces $125 Million Private Placement (Business Wire) +13.24%
09:46AM	Evommune Stock Cools Off After Big Rally On Successful Eczema Trial (Benzinga)
Feb-11-26 07:53AM	Evommunes stock rallies 70% on Phase IIa eczema data (Clinical Trials Arena)
04:33AM	Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill (BioPharma Dive)
Feb-10-26 04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily) +70.87%
12:29PM	Evommune's Stock Surges On Strong Results For New Eczema Drug (Benzinga)
09:12AM	Evommune Nearly Doubles - Has Dupixent Met Its Match In Eczema? (Investor's Business Daily)
07:30AM	Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis (Business Wire)
Jan-19-26 11:28AM	High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 (MarketBeat)
04:05PM	Loading…
Dec-11-25 04:05PM	Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire) -8.53%
Dec-01-25 09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-06-25 03:39PM	What Shutdown? The IPO Window Is Still Open for Some Companies (Barrons.com)
08:55AM	NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading (PR Newswire)
Nov-05-25 07:45PM	Evommune Announces Pricing of its Initial Public Offering (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carver Kyle	Chief Financial Officer	Jul 08 '26	Buy	13.26	1,000	13,260	60,335	Jul 10 07:59 PM
KIRSCH ARTHUR S	Director	Jul 07 '26	Buy	13.30	10,000	133,000	10,000	Jul 08 08:00 PM
Drew Janice Suzann	Chief of Dev. Operations	Jun 22 '26	Option Exercise	3.15	20,000	63,063	87,794	Jun 24 08:00 PM
Drew Janice Suzann	Chief of Dev. Operations	Jun 22 '26	Sale	22.63	20,000	452,600	67,794	Jun 24 08:00 PM
Patel Jeegar Pravinkumar	Chief Scientific Officer	Jun 22 '26	Option Exercise	3.84	1,488	5,714	47,891	Jun 24 08:00 PM
Patel Jeegar Pravinkumar	Chief Scientific Officer	Jun 22 '26	Sale	22.50	1,488	33,480	46,403	Jun 24 08:00 PM
Pena Luis C.	President & CEO	Jun 22 '26	Sale	22.71	7,438	168,917	630,458	Jun 24 07:59 PM
JANICE DREW	Officer	Jun 22 '26	Proposed Sale	21.36	20,000	427,200		Jun 22 04:45 PM
Cohen David E	Director	Jun 02 '26	Sale	20.33	6,056	123,094	17,609	Jun 03 08:03 PM
Patel Jeegar Pravinkumar	Chief Scientific Officer	Jun 01 '26	Option Exercise	3.84	13,512	51,886	63,090	Jun 03 08:02 PM
Patel Jeegar Pravinkumar	Chief Scientific Officer	Jun 01 '26	Sale	22.74	16,687	379,462	46,403	Jun 03 08:02 PM
Pena Luis C.	President & CEO	Jun 01 '26	Sale	22.74	16,787	381,736	637,896	Jun 03 08:02 PM
DAVID COHEN	Director	Jun 02 '26	Proposed Sale	22.17	9,258	205,250		Jun 02 04:37 PM
Moss Gregory S.	Chief Business & Legal Officer	May 28 '26	Option Exercise	1.71	14,223	24,321	75,058	Jun 01 08:00 PM
Moss Gregory S.	Chief Business & Legal Officer	May 28 '26	Sale	22.83	14,223	324,711	60,835	Jun 01 08:00 PM
Carver Kyle	Chief Financial Officer	May 28 '26	Option Exercise	2.99	15,000	44,850	77,510	Jun 01 07:59 PM
Carver Kyle	Chief Financial Officer	May 28 '26	Sale	22.84	18,175	415,117	59,335	Jun 01 07:59 PM
LUIS PENA	Director	Jun 01 '26	Proposed Sale	23.23	24,225	562,747		Jun 01 04:46 PM
JEEGAR PATEL	Officer	Jun 01 '26	Proposed Sale	23.23	18,175	422,205		Jun 01 04:46 PM
GREGORY MOSS	Officer	May 28 '26	Proposed Sale	23.34	14,223	331,965		May 28 04:35 PM
KYLE CARVER	Officer	May 28 '26	Proposed Sale	23.34	25,675	599,254		May 28 04:35 PM
Hopfner Robert Lorne	Director	Dec 19 '25	Buy	17.35	1,000	17,350	4,026	Dec 22 07:07 AM

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

FounderMr. Luis C. Pena

M.B.A.Mr. Kyle Carver CPA

Chief Business & Legal OfficerMr. Gregory S. Moss Esq.

Co-FounderDr. Eugene Andrew Bauer M.D.

Chief Scientific OfficerDr. Jeegar Patel Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EVMN

Evommune Inc

Upgrade your Finviz experience